Celldex/$CLDX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Celldex

Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.

Ticker

$CLDX
Sector
Primary listing

Employees

186

Celldex Metrics

BasicAdvanced
$1.6B
-
-$3.01
1.22
-

What the Analysts think about Celldex

Analyst ratings (Buy, Hold, Sell) for Celldex stock.

Bulls say / Bears say

Robust cash runway with $630.3 million in cash, cash equivalents and marketable securities as of June 30, 2025, providing funding through 2027 and mitigating near-term financing risk (SEC 10-Q)
Strong analyst sentiment with an average rating of “buy” and a median 12-month price target of $60, implying significant upside from current levels (Reuters)
Best-in-class Phase 2 efficacy in chronic spontaneous urticaria: 41% of patients maintained complete response seven months post-dosing and 48% reported no disease-related quality-of-life impact at 76 weeks, underscoring barzolvolimab’s transformative potential (GlobeNewswire)
Net loss widened to $56.6 million in Q2 2025, up from $35.8 million a year earlier, raising concerns over accelerating operating expenses and cash burn (GlobeNewswire)
Revenue fell to $0.7 million in Q2 2025 from $2.5 million in Q2 2024, underscoring limited near-term product or partnership income and continued reliance on grants (GlobeNewswire)
Shares have lost 25.2% year-to-date through Q1 2025, reflecting market skepticism about clinical timelines and the potential for development delays (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 6 Sept 2025.

Celldex Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Celldex Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CLDX

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs